Release Date: 05/07/18 15:33 Summary: Fourth Supplementary Target's Statement Price Sensitive: Yes Download Document 53.03KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%